Paper · 37296177

Optimizing the safety of antibody-drug conjugates for patients with solid tumours.

Tarantino P and 3 others. Nat Rev Clin Oncol, 2023. Cited by 223 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Papers, record 37296177. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37296177

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Optimizing the safety of antibody-drug conjugates for patients with solid tumours.; PubMed
Journal: Nat Rev Clin Oncol; PubMed
Year: 2023; PubMed
Publication types: Journal Article, Review; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/37296177/; PubMed
DOI: https://doi.org/10.1038/s41571-023-00783-w; PubMed
The journal: https://conductscience.org/library/journal-index/101500077; PubMed
Citations, by iCite: 223; iCite
Relative citation ratio, by iCite: 17.9; iCite
Revised in PubMed: 2026-10-31; PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Tarantino P	Paolo
2	Ricciuti B	Biagio
3	Pradhan SM	Shan M
4	Tolaney SM	Sara M

Source PubMed

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Immunoconjugates	Major topic
Neoplasms	Major topic
Antineoplastic Agents	Major topic
Humans

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References166

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	27,075,639	Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.	Anal Chem	2016	https://conductscience.org/library/papers/27075639	PubMed
2	21,551,320	Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target.	J Histochem Cytochem	2011	https://conductscience.org/library/papers/21551320	PubMed
3	31,613,876	Tissue-specific expression of IgG receptors by human macrophages ex vivo.	PLoS One	2019	https://conductscience.org/library/papers/31613876	PubMed
4	28,440,955	Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.	Cancer	2017	https://conductscience.org/library/papers/28440955	PubMed
5	34,678,411	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.	Ann Oncol	2021	https://conductscience.org/library/papers/34678411	PubMed
6	32,728,048	Construction of paclitaxel-based antibody-drug conjugates with a PEGylated linker to achieve superior therapeutic index.	Signal Transduct Target Ther	2020	https://conductscience.org/library/papers/32728048	PubMed
7	32,760,014	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.	Nat Rev Clin Oncol	2020	https://conductscience.org/library/papers/32760014	PubMed
8	24,939,213	Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.	Cancer Chemother Pharmacol	2014	https://conductscience.org/library/papers/24939213	PubMed
9	35,511,740	Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.	Mol Cancer Ther	2022	https://conductscience.org/library/papers/35511740	PubMed
10	33,002,436	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.	Lancet Oncol	2020	https://conductscience.org/library/papers/33002436	PubMed

1 to 10 of 166

See all 166 references

Cited by141

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 223 citations.

PMID	Title	Journal	Year	In Papers	Source
42,988,817	Antibody-drug conjugates: unpacking toxicity profiles and optimized designs for enhanced safety and antitumor efficacy.	Signal Transduct Target Ther	2026	https://conductscience.org/library/papers/42988817	PubMed
42,979,125	Conditionally active antibody‒drug conjugates.	Acta Pharm Sin B	2026	https://conductscience.org/library/papers/42979125	PubMed
42,934,345	Strategies for the intracellular synthesis of bioactive molecules in living cells.	Nat Rev Chem	2026	https://conductscience.org/library/papers/42934345	PubMed
42,883,992	From Dual Targeting to Clinical Validation: A Translational Framework for Bispecific Antibody-Drug Conjugates.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42883992	PubMed
42,855,492	A modular framework for antibody-drug conjugate biomarkers.	Nat Rev Clin Oncol	2026	https://conductscience.org/library/papers/42855492	PubMed
42,835,399	Antibody-Drug Conjugates in Breast Cancer: Therapeutic-Window Engineering, Tumor Heterogeneity, and Immunotherapy Combinations.	Drug Des Devel Ther	2026	https://conductscience.org/library/papers/42835399	PubMed
42,820,303	Antibody-drug conjugates in breast cancer: redefining targeted therapy.	J Clin Invest	2026	https://conductscience.org/library/papers/42820303	PubMed
42,806,387	Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study.	Breast Cancer Res	2026	https://conductscience.org/library/papers/42806387	PubMed
42,768,463	Oral toxicities secondary to TROP2 and HER2-directed antibody drug conjugates: a multicenter retrospective cohort study.	Oncologist	2026	https://conductscience.org/library/papers/42768463	PubMed
42,764,940	Emerging organoids and organoids-on-chip platforms for translational development of antibody‒drug conjugates and next-generation bioconjugates.	Acta Pharm Sin B	2026	https://conductscience.org/library/papers/42764940	PubMed

1 to 10 of 141

See all 141 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37296177

GET https://conductscience.org/api/papers/v1/37296177/references?page=2

API reference For AI assistants